Oncopeptides: Expands Pepaxti Footprint into CEE Region via Salus Partnership - Redeye

Oncopeptides has announced an exclusive distribution and commercialization agreement with Salus for its multiple myeloma drug, Pepaxti, covering 11 countries in Central and Eastern Europe (CEE). This leverages a local partner to unlock a region with an estimated total market potential of SEK150m, driving geographic expansion ahead of the company’s original internal timeline.

Länk till analysen i sin helhet: https://www.redeye.se/research/1169432/oncopeptides-expands-pepaxti-footprint-into-cee-region-via-salus-partnership?utm_source=finwire&utm_medium=RSS